Abstract
RASSF2, potential tumor suppressor gene, acts as a KRAS-specific effectors protein and may promote apoptosis and cell cycle arrest. It stabilizes STK3/MST2 by protecting it from proteasomal degradation. RASSF2 plays a significant role against the inhibition of cancer. MODELLER (9v15) and online servers (I-Tasser, SwissModel, 3D-JigSaw, ModWeb) were utilized to generate 3D structures of the RASSF2 based on homology modeling. A comparison between models predicted by MODELLER (9v15) and Web servers had been checked through utilized evaluation tools. The most potent model for RASSF2 was analyzed and selected for molecular docking studies. The binding pockets were revealed for binding studies through Site Hound. AutoDock Vina and AutoDock4 were utilized for molecular docking, and the attempt of this experiment was to identify the ligands for RASSF2. The selected compounds may act as regulators and regulate the normal activity of RASSF2. It was also analyzed and observed that the selected compounds showed least binding energy and high-affinity binding in predicted top binding domain. The determination of protein function is based on accurate identification of binding sites in protein structures. The binding site is known, and it may allow the ligand type and protein function to be determined by performing in silico and experimental procedures. The detection, comparison, and analysis of binding pockets are pivotal to drug discovery. It proposed that predicted structure is reliable for the structural insights and functional studies. The predicted binding pockets may lead to further analysis (drug discovery), used against cancer study.
Similar content being viewed by others
References
Keyvani V, Kerachian MA (2014) The effect of fasting on the important molecular mechanisms related to cancer treatment. J Fasting Health 2(3):113–118
Yun YH, Kwak M, Park SM, Kim S, Choi JS, Lim HY (2007) Chemotherapy use and associated factors among cancer patients near the end of life. Oncology 72(3–4):164–171
Berliner JL, Fay AM, Cummings SA, Burnett B, Tillmanns T (2013) NSGC practice guideline: risk assessment and genetic counseling for hereditary breast and ovarian cancer. J Genet Couns 22(2):155–163
Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57–70
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674
Brumby AM, Richardson HE (2005) Using Drosophila melanogaster to map human cancer pathways. Nat Rev Cancer 5(8):626–639
Cairns RA, Harris IS, Mak TW (2011) Regulation of cancer cell metabolism. Nat Rev Cancer 11(2):85–95
David CJ, Manley JL (2010) Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev 24(21):2343–2364
Hesson LB, Dunwell TL, Cooper WN, Catchpoole D, Brini AT, Chiaramonte R (2009) The novel RASSF6 and RASSF10 candidate tumour suppressor genes are frequently epigenetically inactivated in childhood leukaemias. Mol Cancer 8(1):42
Ikeda M, Hirabayashi S, Fujiwara N, Mori H, Kawata A, Iida J (2007) Ras-association domain family protein 6 induces apoptosis via both caspase-dependent and caspase-independent pathways. Exp Cell Res 313(7):1484–1495
Allen NPC, Donninger H, Vos MD, Eckfeld K, Hesson L, Gordon L (2007) RASSF6 is a novel member of the RASSF family of tumor suppressors. Oncogene 26(42):6203–6211
Eckfeld K, Hesson L, Vos MD, Bieche I, Latif F, Clark GJ (2004) RASSF4/AD037 is a potential ras effector/tumor suppressor of the RASSF family. Cancer Res 64(23):8688–8693
Chow LSN, Lo KW, Kwong J, Wong AYH, Huang DP (2004) Aberrant methylation of RASSF4/AD037 in nasopharyngeal carcinoma. Oncol Rep 12(4):781–787
Hesson LB, Cooper WN, Latif F (2007) The role of RASSF1A methylation in cancer. Dis Markers 23(1–2):73–87
Cooper WN, Hesson LB, Matallanas D, Dallol A, von Kriegsheim A, Ward R (2009) RASSF2 associates with and stabilizes the proapoptotic kinase MST2. Oncogene 28(33):2988–2998
Vos MD, Ellis CA, Elam C, Ülkü AS, Taylor BJ, Clark GJ (2003) RASSF2 is a novel K-Ras-specific effector and potential tumor suppressor. J Biol Chem 278(30):28045–28051
Maruyama R, Akino K, Toyota M, Suzuki H, Imai T, Ohe-Toyota M (2008) Cytoplasmic RASSF2A is a proapoptotic mediator whose expression is epigenetically silenced in gastric cancer. Carcinogenesis 29(7):1312–1318
Sakamoto-Hojo ET, Mello SS, Pereira E, Fachin AL, Cardoso RS, Junta CM (2003) Gene expression profiles in human cells submitted to genotoxic stress. Mutat Res, Rev Mutat Res 544(2):403–413
Song H, Oh S, Oh HJ, Lim DS (2010) Role of the tumor suppressor RASSF2 in regulation of MST1 kinase activity. Biochem Biophys Res Commun 391(1):969–973
Akino K, Toyota M, Suzuki H, Mita H, Sasaki Y, Ohe-Toyota M (2005) The Ras effector RASSF2 is a novel tumor-suppressor gene in human colorectal cancer. Gastroenterology 129(1):156–169
Imai T, Toyota M, Suzuki H, Akino K, Ogi K, Sogabe Y, Tokino T (2008) Epigenetic inactivation of RASSF2 in oral squamous cell carcinoma. Cancer Sci 99(5):958–966
Zhang Z, Sun D, Van DN, Tang A, Hu L, Huang G (2007) Inactivation of RASSF2A by promoter methylation correlates with lymph node metastasis in nasopharyngeal carcinoma. Int J Cancer 120(1):32–38
Cooper WN, Dickinson RE, Dallol A, Grigorieva EV, Pavlova TV, Hesson LB (2008) Epigenetic regulation of the ras effector/tumour suppressor RASSF2 in breast and lung cancer. Oncogene 27(12):1805–1811
Venter JC, Adams MD, Myers EW, Li PW, Mural RJ et al (2001) The sequence of the human genome. Science 291:1304–1351
Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ (1990) Basic local alignment search tool. J Mol Biol 215:403–410
Sali A, Overington JP (1994) Derivation of rules for comparative protein modeling from a database of protein structure alignments. Protein Sci 3:1582–1596
Eswar N, Eramian D, Webb B, Shen MY, Sali A (2008) Protein structure modeling with MODELLER. Methods Mol Biol 426:145–159
Zhang Y (2008) I-TASSER server for protein 3D structure prediction. BMC Bioinform 9(1):40
Arnold K, Bordoli L, Kopp J, Schwede T (2006) The SWISS-MODEL workspace: a web-based environment for protein structure homology modeling. Bioinformatics 22(2):195–201
Bates PA, Kelley LA, MacCallum RM, Sternberg MJ (2001) Enhancement of protein modeling by human intervention in applying the automatic programs 3D-JIGSAW and 3D-PSSM. Proteins Struct Funct Bioinform 45(S5):39–46
Pieper U, Eswar N, Davis FP, Braberg H, Madhusudhan MS, Rossi A, Eramian D (2006) MODBASE: a database of annotated comparative protein structure models and associated resources. Nucleic Acids Res 34(Suppl 1):D291–D295
Melo F, Devos D, Depiereux E, Feytmans E (1997) ANOLEA: a www server to assess protein structures. ProcIntConfIntellSystMolBiol 5:187–190
Colovos C, Yeates TO (1993) Verification of protein structures: patterns of nonbonded atomic interactions. Protein Sci 2(9):1511–1519
Lovell SC, Davis IW, Arendall WB 3rd, de Bakker PI, Word JM, Prisant MG, Richardson JS, Richardson DC (2005) Structure validation by Calpha geometry: phi, psi and Cbeta deviation. Proteins 50(3):437–450
Hernandez M, Ghersi D, Sanchez R (2009) SITEHOUND-web: a server for ligand binding site identification in protein structures. Nucleic Acids Res 37:W413–W416
Ni L, Li S, Yu J, Min J, Brautigam CA, Tomchick DR (2013) Structural basis for autoactivation of human Mst2 kinase and its regulation by RASSF5. Structure 21(10):1757–1768
Stieglitz B, Bee C, Schwarz D, Yildiz Ö, Moshnikova A, Khokhlatchev A, Herrmann C (2008) Novel type of Ras effector interaction established between tumour suppressor NORE1A and Ras switch II. EMBO J 27(14):1995–2005
Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE (2004) UCSF Chimera—a visualization system for exploratory research and analysis. J Comput Chem 25(13):1605–1612
Mills N (2006) ChemDraw ultra 10.0. J Am Chem Soc 128(41):13649–13650
Acknowledgments
The work is sponsored by CAS-TWAS President’s Fellowship for International Ph.D. Students. Authors are thankful to Zunera Khalid, Mirza A. Hammad, and Rana Adnan Tahir, Bioinformatics Research Laboratory Department of Bioscience, COMSATS Institute of Information Technology, Sahiwal, Pakistan, for their kind guidance in interpreting and suggestions for improving the results.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no competing interests.
Rights and permissions
About this article
Cite this article
kanwal, S., Jamil, F., Ali, A. et al. Comparative Modeling, Molecular Docking, and Revealing of Potential Binding Pockets of RASSF2; a Candidate Cancer Gene. Interdiscip Sci Comput Life Sci 9, 214–223 (2017). https://doi.org/10.1007/s12539-016-0145-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12539-016-0145-z